A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Ioannis A VoutsadakisPublished in: Current oncology (Toronto, Ont.) (2023)
The current systematic review and meta-analysis reports the efficacy of trifluridine/tipiracil with bevacizumab in advanced lines of therapy for metastatic colorectal cancer in the setting of clinical practice outside clinical trials. Discovery of predictive biomarkers of response to trifluridine/tipiracil with bevacizumab will promote the tailoring of this treatment to individual patients to maximize clinical benefit.
Keyphrases
- metastatic colorectal cancer
- clinical trial
- clinical practice
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- small molecule
- peritoneal dialysis
- emergency department
- randomized controlled trial
- high throughput
- prognostic factors
- combination therapy
- study protocol
- adverse drug
- single cell
- patient reported